Profund Advisors LLC boosted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 86.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,465 shares of the company’s stock after purchasing an additional 43,692 shares during the period. Profund Advisors LLC owned about 0.06% of BridgeBio Pharma worth $1,625,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Clear Street Markets LLC acquired a new stake in BridgeBio Pharma in the first quarter valued at $33,000. Quantbot Technologies LP grew its holdings in BridgeBio Pharma by 500.0% during the 1st quarter. Quantbot Technologies LP now owns 4,200 shares of the company’s stock worth $42,000 after acquiring an additional 3,500 shares during the period. Sandia Investment Management LP acquired a new stake in BridgeBio Pharma during the 1st quarter worth about $83,000. Quantamental Technologies LLC bought a new position in shares of BridgeBio Pharma during the 1st quarter worth about $104,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of BridgeBio Pharma during the 3rd quarter worth about $105,000. 90.85% of the stock is currently owned by institutional investors and hedge funds.
BridgeBio Pharma Stock Performance
NASDAQ BBIO opened at $29.24 on Tuesday. BridgeBio Pharma, Inc. has a 52-week low of $6.64 and a 52-week high of $36.36. The company has a market capitalization of $5.09 billion, a P/E ratio of -7.50 and a beta of 1.00. The company has a fifty day moving average of $26.84 and a 200-day moving average of $23.97.
Analyst Ratings Changes
BridgeBio Pharma Profile
BridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
- Five stocks we like better than BridgeBio Pharma
- Market Cap Calculator: How to Calculate Market Cap
- Safeguard your portfolio with these three bargain stocks
- Investing in Construction Stocks
- Membership clubs gain leverage for the consumer rebound
- How to Capture the Benefits of Dividend Increases
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.